Which antipsoriatic drug has the fastest onset of action?-systematic review on the rapidity of the onset of action

Journal of Investigative Dermatology

Volumn 133, Issue 8, 2013, Pages 1963-1970

  Nast, Alexander ^a   Sporbeck, Birte ^a   Rosumeck, Stefanie ^a   Pathirana, Delano ^a   Jacobs, Anja ^a   Werner, Ricardo Niklas ^a   Schmitt, Jochen ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; CYCLOSPORIN A; ETANERCEPT; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ARTICLE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84880331409     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.78     Document Type: Article

References (67)

1. Akhyani M, Chams-Davatchi C, Hemami MR et al. (2010) Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. J Eur Acad Dermatol Venereol 24:1447-51
2. Altmeyer P, Hartwig R, Matthes U (1996) Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients. Hautarzt 47:190-6 (Pubitemid 26117567)
3. Bagel J, Lynde C, Tyring S et al. (2012) Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 67:86-92
4. Barker J, Hoffmann M, Wozel G et al. (2011) Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 165:1109-17
5. Burden AD, Hilton Boon M, Leman J et al. (2010) Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. BMJ 341:c5623
6. Caca-Biljanovska NG, V'Lckova-Laskoska MT (2002) Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J 43:707-12 (Pubitemid 41490286)
7. Carlin CS, Feldman SR, Krueger JG et al. (2004) A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 50: 859-66 (Pubitemid 38691110)
8. Chaudhari U, Romano P, Mulcahy LD et al. (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842-7 (Pubitemid 32539117)
9. Chladek J, Simkova M, Vaneckova J et al. (2008) The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 64: 347-55
10. Costanzo A, Mazzotta A, Papoutsaki M et al. (2005) Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 152:187-9
11. Dogra S, Krishna V, Kanwar AJ (2012) Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol 37: 729-34
12. Elder CA, Moore M, Chang CT et al. (1995) Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 35:865-75
13. Finzi AF, Mozzanica N, Pigatto PD et al. (1993) Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis. Dermatology 187:8-18 (Pubitemid 23223843)
14. Gollnick H, Altmeyer P, Kaufmann R et al. (2002) Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 205:46-53 (Pubitemid 36152961)
15. Gottlieb AB, Langley RG, Strober BE et al. (2012) A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 167:649-57
16. Gottlieb AB, Leonardi C, Kerdel F et al. (2011) Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165:652-60
17. Gottlieb AB, Matheson RT, Lowe N et al. (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627-32 (Pubitemid 37523083)
18. Gribetz CH, Blum R, Brady C et al. (2005) An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 53:73-5 (Pubitemid 40826697)
19. Griffiths CEM, Strober BE, Van De Kerkhof P et al. (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118-28
20. Grossman RM, Thivolet J, Claudy A et al. (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J AmAcad Dermatol 31:68-74 (Pubitemid 24198166)
21. Heydendael VM, Spuls PI, Opmeer BC et al. (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349:658-65 (Pubitemid 36975998)
22. Hick J, Feldman SR (2007) Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol 57:972-6 (Pubitemid 350087350)
23. Higgins JP, Altman DG, Gotzsche PC et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928
24. Hroch M, Chladek J, Simkova M et al. (2008) A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 22:19-24
25. Huang PH, Liao YH, Wei CC et al. (2008) Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study. J Eur Acad Dermatol Venereol 22:923-30
26. Igarashi A, Kato T, Kato M et al. (2012) Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 39: 242-52
27. Katz KA (2005) Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal. J Am Acad Dermatol 53:547-51 (Pubitemid 41196008)
28. Koo J (1998) A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 139:88-95 (Pubitemid 28338069)
29. Krueger GG, Feldman SR, Camisa C et al. (2000) Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 43:281-5 (Pubitemid 30626007)
30. Krueger GG, Papp KA, Stough DB et al. (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47:821-33 (Pubitemid 35403039)
31. Laburte C, Grossman R, Abi-Rached J et al. (1994) Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 130:366-75 (Pubitemid 24204648)
32. Lemme G, Campanati A, Paolinelli M et al. (2007) Diffuse psoriasis plaque type and infliximab: our experience and review of literature. G Ital Dermatol Venereol 142:9-14 (Pubitemid 46607137)
33. Leonardi CL, Kimball AB, Papp KA et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665-74 (Pubitemid 351671883)
34. Leonardi CL, Powers JL, Matheson RT et al. (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014-22 (Pubitemid 37448924)
35. Lui H, Gulliver W, Tan J et al. (2012) A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response. J Drugs Dermatol 11:929-37
36. Mahrle G, Schulze HJ, Farber L et al. (1995) Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 32:78-88
37. Meffert H, Brautigam M, Farber L et al. (1997) Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 77:137-41 (Pubitemid 27201992)
38. Menter A, Feldman SR, Weinstein GD et al. (2007) A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56:e1-15
39. Menter A, Tyring SK, Gordon K et al. (2008) Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 58:106-15 (Pubitemid 350298146)
40. Moher D, Liberati A, Tetzlaff J et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
41. Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 138:456-60 (Pubitemid 28145514)
42. Mrowietz U, Kragballe K, Reich K et al. (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303:1-10
43. Nast A, Boehncke WH, Mrowietz U et al. (2011) [S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges 9(Suppl 2):S1-104
44. Noda S, Mizuno K, Adachi M (2012) Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: Results in a single communitybased hospital. J Dermatol 39:265-8
45. Papp KA, Langley RG, Lebwohl M et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675-84 (Pubitemid 351671884)
46. Pathirana D, Ormerod AD, Saiag P et al. (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23(Suppl 2):1-70
47. Reich K, Langley RG, Papp KA et al. (2011) A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 365:1586-96
48. Reich K, Nestle FO, Papp K et al. (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet 366:1367-74 (Pubitemid 41443403)
49. Reitamo S, Spuls P, Sassolas B et al. (2001) Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145:438-45 (Pubitemid 32953701)
50. Revicki D, Willian MK, Saurat JH et al. (2008) Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 158:549-57 (Pubitemid 351239150)
51. Saurat JH, Langley RG, Reich K et al. (2011) Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol 165:399-406
52. Saurat JH, Stingl G, Dubertret L et al. (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158:558-66 (Pubitemid 351239154)
53. Schafer I, Hacker J, Rustenbach SJ et al. (2010) Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 20:62-7
54. Schmitt J, Zhang Z, Wozel G et al. (2008) Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 159:513-26
55. Scottish Intercollegiate Guidelines Network (SIGN) (2010) Diagnosis and Management of Psoriasis and Psoriatic Arthritis in Adults vol. 121. SIGN: Edinburgh, 72
56. Seston EM, Ashcroft DM, Griffiths CE (2007) Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 143:1175-9 (Pubitemid 47443371)
57. Singh JA, Wells GA, Christensen R et al. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2), CD008794.
58. Smith CH, Anstey AV, Barker JN et al. (2005) British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153:486-97 (Pubitemid 41248202)
59. Strober BE, Crowley JJ, Yamauchi PS et al. (2011) Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165:661-8
60. Torii H, Nakagawa H (2010) Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 59:40-9
61. Tsai T-F, Ho J-C, Song M et al. (2011) Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63:154-63
62. Tyring S, Gordon KB, Poulin Y et al. (2007) Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143:719-26 (Pubitemid 46955730)
63. van de Kerkhof PC, Cambazard F, Hutchinson PE et al. (1998) The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 138:84-9 (Pubitemid 28077942)
64. van de Kerkhof PC, Segaert S, Lahfa M et al. (2008) Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 159:1177-85
65. Vena GA, Galluccio A, Pezza M et al. (2012) Combined treatment with lowdose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled openlabel study. J Dermatolog Treat 23:255-60
66. Yang H-Z, Wang K, Jin H-Z et al. (2012) Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, doubleblind, placebo-controlled multicenter trial. Chin Med J 125:1845-51
67. Yoon HS, Youn JI (2007) A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat 18:286-90 (Pubitemid 47537259)